A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). [electronic resource]
Producer: 20180129Description: 2909-2917 p. digitalISSN:- 2045-7634
- Adult
- Aged
- Antigens, CD34 -- blood
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Breast Neoplasms -- drug therapy
- Camptothecin -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Drug Combinations
- Endothelial Progenitor Cells -- drug effects
- Female
- Gene Frequency
- Glucuronosyltransferase -- genetics
- Heterozygote
- Homozygote
- Humans
- Irinotecan
- Japan
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Oxonic Acid -- administration & dosage
- Pharmacogenetics
- Pharmacogenomic Variants
- Phenotype
- Tegafur -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.